June 19 (Reuters) - Gilead Sciences Inc GILD.O
* Gilead receives approval in Canada for Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis b virus infection
* Gilead Sciences Inc - Health Canada has granted a notice of compliance for vemlidy 25mg tablets
* Gilead Sciences - patients in vemlidy arm also experienced numerically higher rates of normalization of blood serum alanine aminotransferase (alt) levels
* Gilead Sciences Inc - study 108, study 110 met their primary endpoint of non-inferiority to viread Source text for Eikon: ID:nCNWmlrWLa Further company coverage: GILD.O